Advanced searches left 3/3

Cardiac Amyloidosis - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 05 July 2022

* If you want to update the article please login/register

Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

This research will determine whether or not this drug can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart disease. Participants will receive an infusion of the study medication 13 times a week, once every four weeks. Due to TTR amyloidosis, participants are unable to participate in this study if they have a heart disease other than a heart disease.

Source link: https://clinicaltrials.gov/ct2/show/NCT05442047

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions